ARCTURUS THERAPEUTICS ($ARCT) posted quarterly earnings results for Q4 2025 on Tuesday, March 3rd. The company reported earnings of -$1.03 per share, missing estimates of -$0.73 by $0.30. The company also reported revenue of $7,200,000, missing estimates of $18,022,492 by $-10,822,492.
Stock price change since market close: -6.25%
You can see Quiver Quantitative's $ARCT stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ARCTURUS THERAPEUTICS Hedge Fund Activity
We have seen 63 institutional investors add shares of ARCTURUS THERAPEUTICS stock to their portfolio, and 105 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FEDERATED HERMES, INC. removed 1,390,420 shares (-29.6%) from their portfolio in Q4 2025, for an estimated $8,523,274
- BALYASNY ASSET MANAGEMENT L.P. removed 964,985 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $5,915,358
- ARK INVESTMENT MANAGEMENT LLC added 738,378 shares (+39.4%) to their portfolio in Q4 2025, for an estimated $4,526,257
- SCHONFELD STRATEGIC ADVISORS LLC removed 598,072 shares (-89.6%) from their portfolio in Q4 2025, for an estimated $3,666,181
- BANK OF AMERICA CORP /DE/ removed 585,967 shares (-94.5%) from their portfolio in Q4 2025, for an estimated $3,591,977
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 552,179 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $3,384,857
- MORGAN STANLEY removed 491,486 shares (-69.7%) from their portfolio in Q4 2025, for an estimated $3,012,809
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ARCTURUS THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $ARCT in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 11/11/2025
- BTIG issued a "Buy" rating on 10/22/2025
To track analyst ratings and price targets for ARCTURUS THERAPEUTICS, check out Quiver Quantitative's $ARCT forecast page.
ARCTURUS THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $ARCT recently. We have seen 5 analysts offer price targets for $ARCT in the last 6 months, with a median target of $20.0.
Here are some recent targets:
- Yigal Nochomovitz from Citigroup set a target price of $7.0 on 01/06/2026
- Yasmeen Rahimi from Piper Sandler set a target price of $72.0 on 11/11/2025
- Andrew S. Fein from HC Wainwright & Co. set a target price of $9.0 on 11/11/2025
- Yanan Zhu from Wells Fargo set a target price of $20.0 on 10/23/2025
- Thomas Shrader from BTIG set a target price of $23.0 on 10/22/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
